Skip to content
Yog Pharma
CardiovascularPPAR-alpha agonist (fibrate)

Fenofibrate is a PPAR-alpha agonist (fibrate) indicated for severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia. We supply it to US manufacturers of tablets and capsules.

CAS49562-28-9360.8 g/molC20H21ClO4
2D structure of Fenofibrate.

Data from PubChem (CID 3339) and FDA’s substance registry

CAS number

49562-28-9

Molecular formula

C20H21ClO4

Molecular weight

360.8g/mol

FDA UNII

IUPAC name

propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate

InChIKey

YMTINGFKWWXKFG-UHFFFAOYSA-N

Appearance
White or almost white crystalline powder, melting at 79 to 82 °C.
Solubility
Insoluble in water.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Bioavailability depends on particle size, which is why approved products come in so many strengths. State whether your formulation starts from standard or micronized material.

On the US market

Reference product
TricorNDA 019304
Approved ANDAs
37 with a marketed product
Approved forms and strengths
  • Tablet 40 mg to 160 mg, in 7 strengths
  • Capsule 43 mg to 200 mg, in 7 strengths

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com